Royce & Associates LP Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Royce & Associates LP grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 58.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 196,999 shares of the biopharmaceutical company's stock after purchasing an additional 72,988 shares during the quarter. Royce & Associates LP owned approximately 0.15% of Halozyme Therapeutics worth $9,419,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. GSA Capital Partners LLP bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth about $217,000. CIBC Asset Management Inc bought a new stake in Halozyme Therapeutics in the third quarter worth approximately $211,000. Natixis Advisors LLC lifted its stake in Halozyme Therapeutics by 86.7% in the third quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company's stock valued at $6,958,000 after buying an additional 56,461 shares during the period. TrinityPoint Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $214,000. Finally, Quest Partners LLC increased its stake in shares of Halozyme Therapeutics by 1,386.0% in the 3rd quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company's stock valued at $561,000 after acquiring an additional 9,134 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on HALO shares. Benchmark restated a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $62.78.

Remove Ads

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock worth $1,754,451 over the last 90 days. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $0.84 during trading hours on Friday, reaching $65.16. The stock had a trading volume of 4,001,023 shares, compared to its average volume of 1,327,557. The stock's fifty day simple moving average is $58.20 and its 200 day simple moving average is $54.76. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The firm has a market capitalization of $8.02 billion, a PE ratio of 19.00, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.